Search Results - "Perez, J. Rubio"
-
1
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer
Published in European journal of cancer (1990) (01-11-2021)“…In the absence of randomised head-to-head trials, we conducted a population-adjusted indirect treatment comparison (PA-ITC) of phase III trial data to evaluate…”
Get full text
Journal Article -
2
Effect of an antioxidant drink on homocysteine levels in Alzheimer's patients
Published in Journal of the neurological sciences (15-12-2010)“…Abstract Background A large body of evidence supports a role of oxidative stress in Alzheimer disease (AD) and in cerebrovascular disease. Blood levels of…”
Get full text
Journal Article Conference Proceeding -
3
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Published in The New England journal of medicine (19-12-2019)“…Patients with newly diagnosed advanced ovarian cancer were randomly assigned to receive daily niraparib, a PARP inhibitor, or placebo as maintenance therapy…”
Get full text
Journal Article -
4
Serum cytokine profile in Alzheimer's disease patients after ingestion of an antioxidant beverage
Published in CNS & neurological disorders drug targets (01-12-2013)“…The major neuropathologic hallmarks in Alzheimer's disease (AD) consist of neuronal cell loss in selected brain regions, as well as deposition of extracellular…”
Get more information
Journal Article -
5
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
Published in Gynecologic oncology (01-03-2022)“…The phase IIIb OPINION trial (NCT03402841) investigated olaparib maintenance monotherapy in patients without a deleterious or suspected deleterious germline…”
Get full text
Journal Article -
6
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
Published in European journal of cancer (1990) (01-10-2022)“…Background: PAOLA-1/ENGOT-ov25 (NCT02477644) demonstrated a significant progression-free survival (PFS) benefit with maintenance olaparib plus bevacizumab…”
Get full text
Journal Article -
7
The Type of Fat Ingested at Breakfast Influences the Plasma Lipid Profile of Postmenopausal Women
Published in BioMed research international (01-01-2014)“…To assess whether the type of fat ingested at breakfast can modify the plasma lipid profile and other cardiovascular risk variables in postmenopausal women at…”
Get full text
Journal Article -
8
Dostarlimab for the treatment of endometrium cancer and other solid tumors
Published in Drugs of today (Barcelona, Spain : 1998) (01-03-2021)“…The use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely…”
Get full text
Journal Article -
9
HyperlynX: A Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and Radiotherapy in Patients with Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Published in International journal of radiation oncology, biology, physics (01-04-2024)“…The current standard of care for patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) is cisplatin 100 mg/m2 every…”
Get full text
Journal Article -
10
102P Clinical analysis of patients with different KRAS mutations in NSCLC: Different entities analyzed by NGS
Published in Annals of oncology (01-09-2022)Get full text
Journal Article -
11
-
12
2149P Catheter-related thrombosis in cancer patients: Data from the registry of thrombosis and neoplasia of SEOM (TESEO)
Published in Annals of oncology (01-10-2023)Get full text
Journal Article -
13
2083P Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Published in Annals of oncology (01-10-2023)Get full text
Journal Article -
14
Pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results from a single centre
Published in Clinical & translational oncology (01-04-2011)“…Background Pseudomyxoma peritonei (PMP) is a rare, slowly progressive disease whose prognosis depends primarily on the completeness of cytoreduction. The value…”
Get full text
Journal Article -
15
When to think about pediatric congenital pseudoarthrosis of the clavicle? Presentation of 2 cases
Published in Archivos argentinos de pediatría (01-04-2020)“…The congenital pseudoarthrosis of the clavicle is a rare and benign malformation, characterized by the absence of the middle third of the clavicle. It is…”
Get full text
Journal Article -
16
A phase II study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer
Published in Annals of oncology (01-10-2019)Get full text
Journal Article -
17
1062TiP - A phase II study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer
Published in Annals of oncology (01-10-2019)“…New approaches are needed for patients with advanced endometrial cancer (EC) since there is no standard second-line therapy after failure to platinum-based…”
Get full text
Journal Article -
18
1062TiPA phase II study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer
Published in Annals of oncology (01-10-2019)“…Abstract Background New approaches are needed for patients with advanced endometrial cancer (EC) since there is no standard second-line therapy after failure…”
Get full text
Journal Article -
19
First-line ADP-A2M4CD8 T-cell Receptor T-cell Therapy plus Pembrolizumab in Head and Neck Cancers: An Additional Cohort of the Phase 1 SURPASS Trial
Published in International journal of radiation oncology, biology, physics (01-04-2024)“…ADP-A2M4CD8 is an autologous CD4+ and CD8+ T-cell therapy under investigation for treatment of advanced cancers in human leukocyte antigen (HLA)-A*02–eligible…”
Get full text
Journal Article -
20
1688P Impact of immunotherapy on the risk of thromboembolic disease in patients with melanoma
Published in Annals of oncology (01-09-2021)Get full text
Journal Article